Evaxion A/S

Análisis de la acción Evaxion A/S (EVAX)

$3.000

-0.010 (-0.33%)Al cierre

Loading chart…
High
3.070
Open
3.070
VWAP
2.99
Vol
102.02K
Mkt Cap
15.53M
Low
2.900
Amount
305.03K
EV/EBITDA, TTM
-3.79

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

evaxion.ai

AI analysis of Evaxion A/S (EVAX)

hold

Currently, Evaxion Biotech A/S (EVAX) is not a strong buy due to its low current price of $3.01, which is significantly below the analyst price targets of $9 and $10. The stock's RSI of 30.46 indicates it is oversold, but the recent 5-day change of -9.06% raises concerns about momentum. The main risk is the company's net loss of $3.7 million in Q2 2026, which highlights ongoing cash burn and financial instability.

Métricas de valoración

The current forward P/E ratio for Evaxion A/S (EVAX) is 3.57, compared to its 5-year average forward P/E of -3.69.

Forward P/E

Overvalued
5Y Average P/E
-3.69
Current P/E
3.57
Sobrevalorada
2.27
Infravalorada
-9.65

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
-1.47
Current EV/EBITDA
-3.79
Sobrevalorada
-0.21
Infravalorada
-2.74

Forward P/S

Fair
5Y Average P/S
11.59
Current P/S
5.38
Sobrevalorada
28.12
Infravalorada
-4.94

Alphio AI Price Scenarios for EVAX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EVAX

$3.29

Precio del escenario

B

Base

Base · 50%EVAX

$3.03

Precio del escenario

B

Bear

Bear · 25%EVAX

$2.68

Precio del escenario

Cronología de eventos

2026-07-17 (ET)

08:00:00

Evaxion to Present Three-Year Clinical Data for EVX-01 at ESMO Congress

2026-07-12 (ET)

10:00:00

Evaxion Presents New Data Supporting EVX-V1 Vaccine Program

2026-04-17 (ET)

15:20:00

Evaxion Announces New Data Showing AI-Immunology Identifies Vaccine Targets

15:10:00

Evaxion Releases New Data Demonstrating Vaccine Development Potential

2026-04-07 (ET)

08:20:00

Evaxion Completes One-Year Extension of Phase 2 Trial for Personalized Cancer Vaccine EVX-01

Show More Events

Noticias

Show More News

EVAX FAQ — answered by Alphio AI

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections. It operates in the Healthcare sector.

Currently, Evaxion Biotech A/S (EVAX) is not a strong buy due to its low current price of $3.01, which is significantly below the analyst price targets of $9 and $10. The stock's RSI of 30.46 indicates it is oversold, but the recent 5-day change of -9.06% raises concerns about momentum. The main risk is the company's net loss of $3.7 million in Q2 2026, which highlights ongoing cash burn and financial instability.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis